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[57] ABSTRACT 
Hypertension in mammals can be treated by administer-
ing an effective amount of an aminoalkyl phenyl sulfide 
having the formula 
*
ll<j Rs R6 
RJ S-(CnH2n)-N~ 
R1 
R2 R1 
wherein 
(CnH2n)=a linear or branched alkyl chain of 10 car-
bons or less (n= 1-10); 
R1, R1, RJ, R4, Rs,=H, OH, C1-C4-alkyl, C1-C4-alk-
oxy, F, Cl, Br, or I; 
R6 R1 =H, C1-C4-alkyl; 
and the pharmaceutically acceptable salts thereof. The 
hypotensive potential of the compounds may be evalu-
ated by oxygenation with dopamine-beta-hydroxylase. 
8 Claims, No Drawings 
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1 
USE OF AMINOALKYL PHENYL SULFIDE 
DERIVATIVES FOR THE TREATMENT OF 
HYPERTENSION 
2 
the design of therapentic strategies involving the spe-
cific aminoalkyl phenyl sulfides disclosed and enzymes 
that modify them such as the dopamine-beta-hydroxy-
lase and monoamine oxidase. Therefore, this invention 
BACKGROUND OF THE INVENTION 
l. Field of the Invention 
5 also satisfies a need for a fast and effective method of 
evaluating the disclosed hypotensive compounds in 
vitro and allows a more precise method for developing 
effective treatment of hypertension. This invention relates to a method for treating hyper-
tension by the administration of aminoalkyl phenyl 
sulfide derivatives. Moreover, it relates to a method for 10 
evaluating the effectiveness of these compounds 
through oxygenation by dopamine-beta-hydroxylase. 
2. Description of the Prior Art 
Logical approaches to the treatment of hypertension 
require an understanding of the biochemistry and enzy- 15 
mology of the body as it relates to the problems of high 
blood pressure. Prior art discloses the presence of com-
pounds containing phenyl sulfides and amino groups 
biologically active as anti-microbial agents, anti-depres-
sives, appetite suppressants, anti-hypertensives and anti- 20 
inflammatory agents. 
Wehrmeister U.S. Pat. No. 3,318,953 and U.S. Pat. 
No. 4,260,634 discloses a method of synthesis of phenyl-
thioalkylamines and amides thereof together with their 
use as anti-fungal and anti-bacterial agents in metal- 25 
working oil or chemical lubricants. No disclosure relat-
ing to a pharmacological use is made. 
Nair et al. U.S. Pat. No. 3,519,686 discloses 1-(4-
chlorophenyl)-mercapto-2-propylamine and salts 
thereof for use as an anti-depressive or mood elevator. 30 
However, these compounds are not disclosed as anti-
hypertensive agents for use in lowering blood pressure. 
Andrisano, U.S. Pat. No. 3,911,015, discloses the use 
of alkanol-thio-alkylamines and their salts as therapeutic 
agents useful in treating peripheral vasodilatory and 35 
hypertensive problems. Andrisano discloses compounds 
containing 2 aromatic rings connected by an alkyl chain 
containing a thio and a nitro group. This compound is 
clearly distinguishable from the aminoalkyl phenyl sul-
fide derivatives of the present invention in that the two 40 
aromatic groups are required as well as the presence of 
an alkyl group connecting the nitrogen to the phenol 
group. 
SUMMARY OF THE INVENTION 
Accordingly, it is an object of this invention to pro-
vide a novel method for treating hypertension in mam-
mals. 
A further object is to provide a method for treating 
hypertension in mammals by administration of aminoal-
kyl phenyl sulfide derivatives. 
A further object is to evaluate the potential therapeu-
tic value of specific aminoalkyl sulfide derivatives. 
A further object is to provide a method for evaluating 
potential substrate analogs of catecholamine and mono-
amine metabolism. 
Further objects of the invention will become appar-
ent from the disclosure which follows. 
These objects have been attained by a process for 
treating hypertension in mammals comprising adminis-
tering to a mammal an effective amount of an aminoal-
kyl phenyl sulfide derivative having the formula 
wherein: 
(C11H211)=a linear or branched alkyl chain having 10 
carbon atoms or less (n= 1-10) 
Ri, Rz, RJ, R,i, Rs=H, OH, C1-C4-alkoxy, C1-C4-
alkyl, F, Cl, Br, I; 
R6, R6=H, C1-C4-alkyl; 
and pharmaceutically acceptable acid addition salts 
thereof. 
In another embodiment the invention comprises a 
process for evaluating the potential therapeutic value of 
specific aminoalkyl phenyl sulfide derivatives by oxy-
genating them in aqueous solution by the action of 
Lafon, U.S. Pat. No. 4,065,584 discloses anorexigenic 
agents (appetite supressants) and analgesic or anti-in- 45 
flammatory properties of sulphur-containing arylamine 
derivatives. These compounds all include a nitrogen-
containing saturated heterocyclic ring. Therefore, the 
compounds and utilities disclosed by Lafon are different 
from those of the present invention. 
Neustadt, U.S. Pat. No. 4,199,597 discloses poly-
fluoro substituted phenoxy and phenylthio alkanoic 
acids having antihypertensive activity. These com-
pounds are structural! y different from those of the pres-
ent invention in that a polyfluoro-containing group is 55 
present on the aromatic ring. 
50 dopamine-beta-hydroxylase, determining the catalytic 
constant for the oxygenation of the individual aminoal-
kyl phenyl sulfide derivatives and comparing the cata-
lytic constant so obtained with the catalytic constant of 
The prior art fails to disclose a unifying approach to 
hypertensive treatment as is found in the present inven-
tion. The prior art does not disclose the use of the ami-
noalkyl phenyl sulfide derivatives of the present inven- 60 
tion as antihypertensive agents. In a broader sense the 
present invention contains the insight of evaluating a 
compound as a substrate for dopamine-beta-hydroxy-
lase. This use of a purified enzyme system to oxygenate 
the sulfur group reflects a strategy of analysis which 65 
permits evaluation of both the enzymatic parameters 
and products formed by dopamine-beta-hydroxylase 
when acting on the compound of interest. This permits 
standard substrates for dopamine-beta-hydroxylase in 
this assay. 
DETAILED DESCRIPTION OF THE 
INVENTION AND PREFERRED 
EMBODIMENTS 
In the compounds used in the process of this inven-
tion, the phenyl ring can be substituted or unsubstituted. 
Suitable substituents R1-R5 include C1-C4-alkyl groups, 
such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-
butyl, sec-butyl, and t-butyl; C1-C4-alkoxy groups such 
as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 
isobutoxy, sec-butoxy, t-butoxy, hydroxy, and halogen, 
such as fluorine, chlorine, bromine and iodine. The 
amino group may be substituted or unsubstituted. Suit-
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able substituents include C1-C4 alkyl groups such as 
those enumerated above. The alkyl chain between the 
sulfur atom and the amino group may be any linear or 
branched chain divalent hydrocarbon group. Suitable 
groups include methylene, ethylene, 1,3-propylene 1,4- 5 
butylene, 1,6-hexylene, octamethylene, decamethylene, 
2-methyl-1,3-propylene, 3-methyl-1,5-pentylene, 3-
ethyl-1,5-pentylene, 2-ethyl-1,6-pentylene, 2-ethyl-1,6-
hexylene, 2-ethyl-1,8-octylene, S-methyl-1,9-nonylene, 
and the like. 10 
Suitable compounds useful in the process of this in-
vention include 2-aminoethyl phenyl sulfide, 2-(me-
thylamino)ethyl phenyl sulfide, 2-(dimethylamino)ethyl 
phenyl sulfide, 2-(ethylamino)ethyl phenyl sulfide, 2-(n-
propylamino)ethyl phenyl sulfide, 2-(n- 15 
butylamino)ethyl phenyl sulfide, 2-aminoethyl 4-
hydroxyphenyl sulfide, 2-aminoethyl 3,4-dihydrox-
yphenyl sulfide, 2-aminoethyl 3,5-dihydroxyphenyl 
sulfide, 2-aminoethyl 4-methyl phenyl sulfide, 2-amino-
ethyl 2,4-dimethyl phenyl sulfide, 2-aminoethyl 4-ethyl- 20 
phenyl sulfide, 2-aminoethyl 4-propylphenyl sulfide, 
2-aminoethyl 4-butylphenyl sulfide, 2-aminoethyl 4-
methoxyphenyl sulfide, 2-aminoethyl 4-ethoxy phenyl 
sulfide, 2-aminoethyl 4-propoxyphenol sulfide, 2-amino-
ethyl 4-butoxyphenyl sulfide, 2-aminoethyl 3,4-dime- 25 
thoxyphenyl sulfide, 2-aminoethyl 3,4,5-trimethoxyphe-
nyl sulfide, 3-aminopropyl phenyl sulfide, 4-aminobutyl 
phenyl sulfide, 6-aminohexyl phenyl sulfide, 8-aminooc-
tyl phenyl sulfide, 10-aminodecyl phenyl sulfide, 6-
amino-2-ethylhexyl phenyl sulfide, 3-amino-2-methyl- 30 
propyl 3,4-dihydroxyphenyl sulfide, 4-amino-3-methyl-
butyl 3,4-dimethoxyphenyl sulfide, 4-methylamino-3-
methylbutyl 3,4-dimethoxyphenyl sulfide, and the like. 
The compounds used in the process of this invention 
are readily synthesized by methods known to those 35 
skilled in the art. For example, the procedure disclosed 
by Wehrmeister, U.S. Pat. Nos. 3,318,953 and 4,260,634 
may be used to prepare compounds suitable for the 
method of treatment of this invention. 
The compounds used in the process of this invention 40 
may also be used in the form of their acid addition salts 
with non-toxic pharmaceutically acceptable acids. Such 
salts include the hydrochloride, sulfate, hydrobromide, 
citrate, acetate, gluconate, and the like. 
A preferred compound for use in the process of this 45 
invention is 2-aminoethyl phenyl sulfide. 
In practicing the process of this invention the anti-
hypertensive compounds may be administered orally, 
parenterally or rectally and may be formulated in com-
positions and dosage forms for such administration. In 50 
these compositions and dosage forms the compounds 
are admixed with conventional non-toxic pharmaceuti-
cal excipients. Solid dosage forms for oral administra-
tion include capsules, tablets, pills, powders, and gran-
ules. In such solid dosage forms, the active compound is 55 
admixed with at least one inert diluent such as sucrose, 
lactose, or starch. Such dosage forms can also comprise, 
as is normal practice, additional substances other than 
inert diluents, e.g., lubricating agents such as magne-
sium stearate. In the case of capsules, tablets, and pills, 60 
the dosage forms may be also comprise buffering 
agents. Tablets and pills can also be prepared with an 
enteric coating. 
Liquid dosage forms for oral administration include 
pharmaceutically acceptable emulsions, solutions, sus- 65 
pensions, syrups, and elixirs containing inert diluents 
commonly used in the art, such as purified water and 
aleohols. Besides inert diluents, such compositions can 
also include adjuvants, such as wetting agents, emulsify-
ing and suspending agents, and sweetening, flavoring, 
and perfuming agents. Preparations according to this 
invention for parenteral administration include sterile 
aqueous or non-aqueous solutions, suspensions or emul-
sions. Examples of non-aqueous solvents or vehicles are 
propylene glycol, polyethylene glycol, vegetable oils 
such as olive oil and injectable organic esters such as 
ethyl oleate. 
Compositions for rectal administration are supposito-
ries which may contain in addition to the active sub-
stance, excipients such as cocoa butter or a suppository 
wax. 
The dosage of active ingredient in the compositions 
of this invention may be varied; however, it is necessary 
that the amount of the active ingredient be such that a 
suitable dosage form is obtained. The selected dosage 
depends upon the desired therapeutic effect, on the 
route of administration, and on the duration of the treat-
ment. Generally, dosage levels of between 0.5 to 100 
mg/kg of body weight daily are administered to mam-
mals to obtain effective relief of hypertension. A pre-
ferred dosage level is 1.0 to 10.0 mg/kg of body weight. 
In treating hypertension in mammals by the method 
of this invention, it is preferred to administer the amino-
alkyl phenyl sulfide in combination with a monoamine 
oxidase inhibitor, which may have the:effect of prolong-
ing the life of the active compounds in the body. 
The combination of aminoalkyl phenyl sulfide deriva-
tives and monoamine oxidase inhibitors such as clorgy-
line, deprenyl, nardil (phenethylhydrazine sulfate) or 
others currently in clinical use may protect the sulfide 
or sulfoxide product and therefore allow a longer active 
period in the body, resulting in an increased anti-hyper-
tensive effect. 
Although the exact mechanism by which the com-
pounds used in the process of this invention exert their 
physiological effect is uncertain, and applicants do not 
wish to be bound by any theoretical considerations, it is 
possible that the compounds may play the role, at least 
in part, of false neurotransmitters. According to Wil-
liams, "Textbook of Endocrinology," W. D. Saunders 
Co., 1974, p. 292, the criteria for a false neurotransmit-
ter include the following: 
(1) Generally, they are not normally present in the 
sympathetic neurons in significant quantities. 
(2) They can be made to accumulate in the nerve 
endings at the same site as the natural transmitters. 
(3) They must be held in the same storage sites, re-
leased by the same nerve stimulation, and depleted by 
drugs that deplete norepinephrine. 
The compounds used in the process of this invention 
bear some resemblence to the catecholamines which are 
involved in neurotransmission in that they can act as 
excellent substrates for dopamine-beta-hydroxylase. 
Early assertions of false neurotransmitters such as aldo-
met (a-methyldopamine) proved to be incorrect. 
("Pharmacological Basis of Therapeutics," Ed. by L. 
Goodman and Alfred Gilman, 4th Ed. 1970, and 6th Ed. 
1980, McMillan Co.). 
The disclosed aminoalkyl phenyl sulfide derivatives 
or their enzymatic oxygenation products may function 
as false neurotransmitters. Dopamine-beta-hydroxylase 
[EC 1.14.2.1 ], a copper-containing monooxygenase 
present in a variety of mammalian tissues, catalyzes the 
conversion of dopamine to norepinephrine, thus playing 
a key role in the biosynthethetic conversion of potent 
neurotransmitters and in the production of adrenaline. 
5 
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The first demonstration of sulfoxidation by dopamine-
beta-hydroxylase was reported with phenyl 2-amino-
ethyl sulfide as substrate (S. W. May and R. S. Phillips, 
J. Am. Chem. Soc. 102, 5983-5984, 1980). 
the body, it would be expected that the presence in the 
body of a competitive substrate would act to decrease 
the amount of catecholamines produced, and thereby 
The effectiveness of the compounds used in the pro-
cess of this invention as anti-hypertensive agents can be 
evaluated by such an enzymatic oxygenation process. In 
this process the aminoalkyl phenyl sulfide is contacted 
with the enzyme dopamine-beta-hydroxylase in aque-
ous solution in the presence of molecular oxygen, an 
electron donor, e.g. hexacyanoferrate (II) or ascorbate, 
and the necessary cofactors for the enzyme, such as a 
source of copper (II) ions, and at a pH range, main-
tained by a suitable buffer, of 3 to 8, preferably about 5 
to 6, and at a temperature of 20° to 47° C., preferably 
about 37° C. 
5 have an hypotensive effect. 
Therefore, by a comparison of the relative values of 
the catalytic constants for the various aminoalkyl 
phenyl sulfide substrates, the compounds which have 
10 superior hypotensive activity can be selected. 
Having now fully described the invention, it will be 
apparent to one of ordinary skill in the art that many 
changes and modifications may be made thereto with-
15 out departing from the spirit or scope of the invention as 
set· forth herein. It is preferred to use purified enzyme, e.g. dopamine-
beta-hydroxylase prepared from bovine adrenals by a 
modification of the method of Ljones et al., European 
Journal of Biochemistry 1976, 61, 525-533. It is pre- 20 
ferred to µse an enzyme having an activity of 12-15 
units per milligram in the presence of fumarate and 
copper and hexacyanoferrate(II) or ascorbate as the 
electron donor. The presence of copper greatly acceler-
ates the oxygenation of the substrate and, hence it is 25 
preferred that copper (II) ion be present in the solution 
at a concentration of 3-5 micromolar. The oxygenation 
is also accelerated by the presence of fumarate. Accord-
ingly, it is preferred that fumarate be present in the 
reaction mixture in a concentration of at least 10 mil- 30 
limolar. 
The preferred concentration of hexacyanoferrate(II), 
when it is used as the electron donor, is about 2 millimo-
lar. When ascorbic acid is used as an electron donor it is 
preferred that it be present in a concentration of about 35 
10 millimolar. When ascorbic acid is used as the elec-
tron donor it is also preferred that about 200 micro-
grams per milliliter of catalase be present in the reaction 
mixture. 
The progress of the oxygenation reaction may be 40 
followed by any .convenient method. For example, 
when hexacyanoferrate(II) is used as the electron do-
nor, the reaction may be followed spectrophotometri-
cally, by measuring the optical absorbance at 420 nm; 
when ascorbic acid is used as the electron donor the 45 
reaction may be followed by measuring the oxygen 
uptake using a polarographic electrode and an oxygen 
monitor. 
The catalytic constants for the oxygenation of each 
substrate are then determined by conventional proce- 50 
<lures such as the method of Eisenthal and Cornish-
Bowden, (1974) Biochem. J., 139, 715-720, or by using 
the computer program of Cleland to fit the hyperbolic 
form of the Michaelis-Menten equation (Cleland, W. 
W., Adv. Enzymol. Relat. Areas Mol. Biol. 1967, 29, 55 
1-32). 
In order to evaluate the potential hypotensive activ-
ity of aminoalkyl phenyl sulfides, the catalytic constants 
for each of the compounds are compared with the cata-
lytic constants for standard substrates for dopamine- 60 
beta-hydroxylase such as tyramine and 2-phenylethyla-
mine. The greater the catalytic constant o.f the particu-
lar substrate, the more reactive the substrate is with the 
enzyme dopamine-beta-hydroxylase. The more reactive 
the substrate is with the enzyme, the greater its potential 65 
competitive effect with the natural substrate in the 
body. Since dopamine-beta-hydroxylase is a major en-
zyme in the synthetic pathway of the catecholamines in 
EXAMPLE 1 
,A reaction solution was prepared having concentra-
~icms qf 5 micromolar CuS04, 10 mM sodium Jumarate, 
2 ,mM KAFe(CN)6, .0.1 M 2-(N-morpholino)ethylsul-
fonic acid (Mes) buffer, having a pH of 6.0. Several 
reaction mixtures were prepared by dissolving a fixed 
amount of dopamine-beta-hydroxylase and varied 
amounts of substrate in constant volumes of the reaction 
solution. The rate of oxygenation of the substrate in 
each reaction mixture was measured spectrophotomet-
rically by observing the absorption spectrum of the 
Fe(CN)64- at 420 nm at 37° C. The catalytic constants 
kcal for each substrate were determined using the proce-
dure of Eisenthal and Cornish-Bowden, Biochem J. 
1974, 139, 715-720, or that of Cleland, Adv. Enzymol. 
Relat. Areas Mol. Biol. 1967, 29, 1-32. The Michaelis-
Mente!1 constants for each enzyme-substrate combina-
tion were also determined. Three substrates were inves-
tigated, 2-phenethylamine(standard), 3-phenylethyla-
mine (analog), 2-aminoethyl phenyl sulfide (compound 
of the invention). The kca1 and ratio of kcar!Km for each 
substrate are tabulated in Table I below. 
EXAMPLE2 
A reaction solution was prepared having concentra-
tions of 5 micromolar CuS04, 10 mM sodium fumarate, 
10 mM ascorbic acid, 200 microgram/mL catalase, and 
0.1 M acetate buffer, having a pH of 5.0. Several reac-
tion mixtures were prepared by dissolving a fixed 
amount of dopamine-beta-hydroxylase and varied 
amounts of substrate in constant volumes of the reaction 
solution. The rate of oxygenation of the substrate was 
determined by measuring 02 uptake at 37° C. with a 
Clark polarographic electrode and a YSI Model 53 02 
monitor. The catalytic constant Kcal and Km for each 
substrate were determined by the same procedure as in 
Example 1. The same three substrates were investigated 
as in Example 1, and the results are tabulated in Table 1 
below. The reaction for 2-aminoethyl phenyl sulfide 
may be symbolized by the following equation: 
4,415,591 
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@H,CH,NH, + to:':::::od~~" do•~] 
Dopamine-
beta-
Hydroxylase 
0 
II 
l S-CH2CH2NH2 @ + Dehydroascrobate [or oxidized 
electron donor] 
s 
10 
1. A method for treating hypertension in mammals 
comprising administering to said mammal an effective 
amount of an aminoalkyl phenyl sulfide having the 
formula: 
*
R4 Rs R
6 
RJ S-(CnH2n)-N~ 
R1 
Ri R1 
wherein 
(CnH2n)=a linear or branched alkyl chain of 10 car-
bons or less (n= 1-10); 
R1, Rz, R3, R4, Rs=H, OH, C1-C4 alkyl, C1-C4-
alkoxy, F, Cl, Br, or I; 
R6, R1=H, C1-C4-alkyl; 
or a pharmaceutically acceptable salt thereof. 
2. The method of claim 1 wherein R1, Rz, RJ, R4, and 
Rs are selected from the group consisting of H, OH, 
C1-C4-alkyl, and C1-C4-alkoxy. 
It may be seen from an inspection of the data in Table I 15 
that the compound of this invention, 2-aminoethyl 
phenyl sulfide, is oxygenated at a rate which is much 
faster than the carbon analog 3-phenylpropylamine_ 
Thus this assay provides a method for evaluating the 20 
relative rates of oxygenation of the various aminoalkyl 
phenyl sulfides which may be used in judging their 
potential for in vivo activity, in particular anti-hyper-
tensive activity. 3. The method of claim 1 wherein Rt. Rz, RJ, R4, and 
25 Rs are hydrogen. TABLE I 
Oxygenated 
substrate 
Electron Donor 
Fe(CN)64- Ascorbic acid 
kcar.s- 1 kcat1Km,M- 1s- kca1.s-l kca11Km,M- 1s-I 
-1 
Having now fully described the invention, it will be 
apparent to one of ordinary skill in the art that many 
changes and modifications can be made thereto without 40 
departing from the spirit or scope of the invention as set 
forth herein. 
What is claimed as new and desired to be secured by 
Letters Patent of the United States is: 
45 
50 
55 
60 
65 
4. The method of claim 1 wherein R6 and R1 are 
hydrogen. 
5. The method of claim 1 wherein said aminoalkyl 
phenyl sulfide is 2-aminoethyl phenyl sulfide. 
6. The method of claim 1 wherein said effective 
amount is 0.5 to 100 mg/kg of body weight of said 
mammal. 
7. The method of claim 1 wherein said effective 
amount is 1.0 to 10 mg/kg of body weight of said mam-
mal. 
8. A pharmaceutical composition comprising a com-
pound of the formula as in claim 1, in an amount effec-
tive for treatment of hypertension in mammals, a clini-
cally utilized monoamine oxidase inhibitor, and a phar-
maceutically acceptable non-toxic excipient, said mono-
amine oxidase inhibitor being selected from the group 
of clinically utilized monoamine oxidase inhibitors con-
sisting of clorgyline, deprenyl, and nardil. 
* * * * * 
